Video Series

Medical experts discuss unmet needs surrounding treatment of multiple myeloma.

Experts discuss evolving strategies in ER+/HER2– metastatic breast cancer treatment, combining endocrine and targeted therapies, and leveraging specific mutations for optimal patient outcomes.

Key opinion leaders open a discussion surrounding CLL and SLL, and describing unique characteristics of each disease state.

Richard Adler, MD, FACS, Assistant Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins Institute, and Director of Ophthalmology Services at Belcara Health, discusses the critical unmet needs in Dry Eye Disease (DED) therapies and explores the potential impact of new agents in addressing these challenges.

A panel of experts explore desmoid tumor clinical characteristics, heterogeneity, and diagnostic complexities for optimal treatment strategies.

Medical professionals discuss strategies and best practices for recognizing and mitigating immunotherapy toxicities through multidisciplinary collaboration and use of monitoring technology.

The panel emphasizes the role of multidisciplinary tumor boards in optimizing oncology care in nonmelanoma skin cancers.

Therapeutic and financial considerations of EVT are explored by a medical expert.

An expert panel unpacks challenges in implementing bispecific therapies for operational excellence.

Dr Haumschild leads a discussion highlighting key care team members shaping the bispecific therapy decision-making processes.

A panel of medical experts break down the pathophysiology and current treatment landscape surrounding Ph+ ALL.

Amy Nguyen Howell, MD, MBA, highlights health equity issues and racial disparities in the prevalence and treatment of diabetic macular edema and emphasizes the influence of social determinants of health aspects on patient outcomes.

Novel therapies in MDS treatment are evaluated by a panel of experts led by Dr Haumschild.

Key opinion leaders discuss the process of adapting MDS treatment strategies for optimal impact of care.

Elizabeth Yeu, MD, discusses complications that may arise from inadequate treatment of Demodex blepharitis.

Elizabeth Spencer, MD, discusses various treatments for eosinophilic esophagitis (EoE) across age groups, highlighting the role of dietary modifications, proton pump inhibitors, swallowed corticosteroids, and monoclonal antibodies.

Michael D. Shapiro, DO, and Erin D. Michos, MD, MHS, explain the importance of the global Lp(a)HERITAGE study, emphasizing prevalence of elevated Lp(a) among different populations and the evolving approach to assessing Lp(a) levels.

Aaron Gerds, MD, MS, reviews myeloid disorder myelofibrosis and presents diverse symptoms, from blood count variations to spleen enlargement.

Jaime Murillo, MD, explores genetic inheritance patterns of Lp(a) from childhood to adulthood, highlighting stability, factors affecting measurement, and awareness challenges among those in the health care community.

Elizabeth Spencer, MD, discusses how EoE can affect children's activities and social interactions.

Mark Metersky, MD, FCCP, illustrates the pathology of bronchiectasis.

Key opinion leaders highlight the importance of identifying and treating dry eye disease to mitigate long-term economic burdens.

Professionals highlight considerations for the addition of cost-effective, statistically significant therapies to payer formularies.

Key opinion leaders underscore the importance of a multidisciplinary approach that can break down barriers and advance CSCC and BCC therapy.

Experts explore the optimal sequencing of immunotherapy relative to radiation therapy in CSCC and BCC care.

Russell P. Gollard, MD, FACP, highlights the impact of recent advances in hemophilia A treatment on formulary decisions and management approaches.

Panelists provide final considerations surrounding biosimilar usage and considerations for optimal patient care.

Key topics for patient-provider conversations within the biosimilar landscape are highlighted by expert panelists.